Entry - #300636 - IMMUNODEFICIENCY 33; IMD33 - OMIM
# 300636

IMMUNODEFICIENCY 33; IMD33


Alternative titles; symbols

INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 2, FORMERLY; IPD2, FORMERLY


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
Xq28 Immunodeficiency 33 300636 XLR 3 IKBKG 300248
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- X-linked recessive
HEAD & NECK
Teeth
- Delayed eruption of teeth (in some patients)
- Conical teeth (in some patients)
- Hypodontia (in some patients)
IMMUNOLOGY
- Recurrent infections
- Variably impaired immunologic function
- Dysgammaglobulinemia
- Increased IgM (in some patients)
- Hypogammaglobulinemia
- Aberrant IgG and IgA
- Poor class-switching in B cells
- Poor response to vaccination, particularly to pneumococcus
- T-cell dysfunction (in some patients)
- Normal immunologic parameters (in some patients)
- Susceptibility to disseminated mycobacterial infections
- Susceptibility to pneumococcus
- Susceptibility to H. influenza
- Impaired cytokine production, including IL6, IL12, and gamma-interferon
- Impaired response to IL1B and TNFA
- Impaired NK cytotoxic function
- Decreased activation of the NFKB signaling pathway
MISCELLANEOUS
- Onset usually in infancy or early childhood
- Highly variable severity
- Laboratory abnormalities may be subtle and may change over time
- Treatment with IVIg is beneficial
- Carrier mothers may have conical teeth or hypodontia
MOLECULAR BASIS
- Caused by mutation in the inhibitor of nuclear factor kappa B kinase, regulatory subunit gamma gene (IKBKG, 300248.0018)
Immunodeficiency (select examples) - PS300755 - 143 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.33 Immunodeficiency 38 AR 3 616126 ISG15 147571
1p36.33 ?Immunodeficiency 16 AR 3 615593 TNFRSF4 600315
1p36.23 Immunodeficiency 109 with lymphoproliferation AR 3 620282 TNFRSF9 602250
1p36.22 Immunodeficiency 14B, autosomal recessive AR 3 619281 PIK3CD 602839
1p36.22 Immunodeficiency 14A, autosomal dominant AD 3 615513 PIK3CD 602839
1p35.2 Immunodeficiency 22 AR 3 615758 LCK 153390
1p34.2 Immunodeficiency 24 AR 3 615897 CTPS1 123860
1p22.3 ?Immunodeficiency 37 AR 3 616098 BCL10 603517
1q21.3 Immunodeficiency 42 AR 3 616622 RORC 602943
1q23.3 Immunodeficiency 20 AR 3 615707 FCGR3A 146740
1q24.2 ?Immunodeficiency 25 AR 3 610163 CD247 186780
1q25.3 Immunodeficiency 113 with autoimmunity and autoinflammation AR 3 620565 ARPC5 604227
1q25.3 Immunodeficiency 70 AD 3 618969 IVNS1ABP 609209
1q31.3-q32.1 Immunodeficiency 105, severe combined AR 3 619924 PTPRC 151460
2p16.1 Immunodeficiency 92 AR 3 619652 REL 164910
2p11.2 Immunodeficiency 116 AR 3 608957 CD8A 186910
2q11.2 Immunodeficiency 48 AR 3 269840 ZAP70 176947
2q24.2 Immunodeficiency 95 AR 3 619773 IFIH1 606951
2q32.2 Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive AR 3 613796 STAT1 600555
2q32.2 Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant AD 3 614162 STAT1 600555
2q32.2 Immunodeficiency 31A, mycobacteriosis, autosomal dominant AD 3 614892 STAT1 600555
2q33.2 ?Immunodeficiency 123 with HPV-related verrucosis AR 3 620901 CD28 186760
2q35 Immunodeficiency 124, severe combined AR 3 611291 NHEJ1 611290
3p22.2 Immunodeficiency 68 AR 3 612260 MYD88 602170
3q21.3 Immunodeficiency 21 AD 3 614172 GATA2 137295
3q21.3 ?Immunodeficiency 128 AR 3 620983 COPG1 615525
3q29 Immunodeficiency 46 AR 3 616740 TFRC 190010
4p14 Immunodeficiency 129 AR 3 618307 RHOH 602037
4q24 Immunodeficiency 75 AR 3 619126 TET2 612839
4q35.1 {Immunodeficiency 83, susceptibility to viral infections} AD, AR 3 613002 TLR3 603029
5p15.2 {Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection} AD 3 619986 OTULIN 615712
5p13.2 Immunodeficiency 104, severe combined AR 3 608971 IL7R 146661
5q11.2 ?Immunodeficiency 94 with autoinflammation and dysmorphic facies AD 3 619750 IL6ST 600694
5q13.1 Immunodeficiency 36 AD 3 616005 PIK3R1 171833
5q31.1 Immunodeficiency 93 and hypertrophic cardiomyopathy AR 3 619705 FNIP1 610594
5q31.1 Immunodeficiency 117, mycobacteriosis, autosomal recessive AR 3 620668 IRF1 147575
5q33.3 Immunodeficiency 29, mycobacteriosis AR 3 614890 IL12B 161561
5q35.1 Immunodeficiency 40 AR 3 616433 DOCK2 603122
5q35.1 Immunodeficiency 81 AR 3 619374 LCP2 601603
6p25.3 Immunodeficiency 131 AD, AR 3 621097 IRF4 601900
6p25.2 Immunodeficiency 57 with autoinflammation AR 3 618108 RIPK1 603453
6p21.33 ?Immunodeficiency 127 AR 3 620977 TNF 191160
6p21.31 Immunodeficiency 87 and autoimmunity AR 3 619573 DEF6 610094
6p21.1 Immunodeficiency 126 AR 3 620931 PTCRA 606817
6q14.1 Immunodeficiency 23 AR 3 615816 PGM3 172100
6q15 Immunodeficiency 60 and autoimmunity AD 3 618394 BACH2 605394
6q23.3 Immunodeficiency 27B, mycobacteriosis, AD AD 3 615978 IFNGR1 107470
6q23.3 Immunodeficiency 27A, mycobacteriosis, AR AR 3 209950 IFNGR1 107470
7p22.2 Immunodeficiency 11A AR 3 615206 CARD11 607210
7p22.2 Immunodeficiency 11B with atopic dermatitis AD 3 617638 CARD11 607210
7q22.1 Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia AR 3 617718 ARPC1B 604223
7q22.3 Immunodeficiency 97 with autoinflammation AR 3 619802 PIK3CG 601232
8p11.21 Immunodeficiency 15B AR 3 615592 IKBKB 603258
8p11.21 Immunodeficiency 15A AD 3 618204 IKBKB 603258
8q11.21 Immunodeficiency 26, with or without neurologic abnormalities AR 3 615966 PRKDC 600899
8q11.21 Immunodeficiency 54 AR 3 609981 MCM4 602638
8q21.13 Immunodeficiency 130 with HPV-related verrucosis AR 3 618309 IL7 146660
9q22.2 Immunodeficiency 82 with systemic inflammation AD 3 619381 SYK 600085
9q34.3 Immunodeficiency 103, susceptibility to fungal infection AR 3 212050 CARD9 607212
10p15.1 Immunodeficiency 41 with lymphoproliferation and autoimmunity AR 3 606367 IL2RA 147730
10p13 Immunodeficiency 80 with or without cardiomyopathy AR 3 619313 MCM10 609357
11p15.5 ?Immunodeficiency 39 AR 3 616345 IRF7 605047
11p15.4 Immunodeficiency 10 AR 3 612783 STIM1 605921
11q12.1 Immunodeficiency 77 AD 3 619223 MPEG1 610390
11q13.3 Immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction AR 3 613759 FADD 602457
11q13.4 Immunodeficiency 122 AR 3 620869 POLD3 611415
11q23.3 Immunodeficiency 18, SCID variant AR 3 615615 CD3E 186830
11q23.3 Immunodeficiency 18 AR 3 615615 CD3E 186830
11q23.3 Immunodeficiency 19, severe combined AR 3 615617 CD3D 186790
11q23.3 Immunodeficiency 17, CD3 gamma deficient AR 3 615607 CD3G 186740
11q23.3 ?Immunodeficiency 59 and hypoglycemia AR 3 233600 HYOU1 601746
12p13.31 Immunodeficiency 79 AR 3 619238 CD4 186940
12q12 Immunodeficiency 67 AR 3 607676 IRAK4 606883
12q13.13-q13.2 Immunodeficiency 72 with autoinflammation AR 3 618982 NCKAP1L 141180
12q13.3 Immunodeficiency 44 AR 3 616636 STAT2 600556
12q15 ?Immunodeficiency 69, mycobacteriosis AR 3 618963 IFNG 147570
12q24.13 Immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia AD 3 618042 OAS1 164350
12q24.31 Immunodeficiency 9 AR 3 612782 ORAI1 610277
13q33.1 Immunodeficiency 78 with autoimmunity and developmental delay AR 3 619220 TPP2 190470
14q11.2 Immunodeficiency 7, TCR-alpha/beta deficient AR 3 615387 TRAC 186880
14q11.2 ?Immunodeficiency 108 with autoinflammation AR 3 260570 CEBPE 600749
14q12 Immunodeficiency 115 with autoinflammation AR 3 620632 RNF31 612487
14q12 Immunodeficiency 65, susceptibility to viral infections AR 3 618648 IRF9 147574
14q32.2 Immunodeficiency 49, severe combined AD 3 617237 BCL11B 606558
14q32.32 Immunodeficiency 132A AD 3 614849 TRAF3 601896
14q32.32 Immunodeficiency 132B AD 3 621096 TRAF3 601896
15q14 Immunodeficiency 64 AR 3 618534 RASGRP1 603962
15q21.1 Immunodeficiency 43 AR 3 241600 B2M 109700
15q21.2 Immunodeficiency 86, mycobacteriosis AR 3 619549 SPPL2A 608238
16p12.1 Immunodeficiency 56 AR 3 615207 IL21R 605383
16p11.2 Immunodeficiency 52 AR 3 617514 LAT 602354
16p11.2 Immunodeficiency 8 AR 3 615401 CORO1A 605000
16q22.1 Immunodeficiency 58 AR 3 618131 CARMIL2 610859
16q22.1 Immunodeficiency 121 with autoinflammation AD 3 620807 PSMB10 176847
16q24.1 Immunodeficiency 32A, mycobacteriosis, autosomal dominant AD 3 614893 IRF8 601565
16q24.1 Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive AR 3 226990 IRF8 601565
17q11.2 ?Immunodeficiency 13 AD 3 615518 UNC119 604011
17q12-q21.1 ?Immunodeficiency 84 AD 3 619437 IKZF3 606221
17q21.31 Immunodeficiency 112 AR 3 620449 MAP3K14 604655
17q21.32 ?Immunodeficiency 88 AR 3 619630 TBX21 604895
18q21.32 Immunodeficiency 12 AR 3 615468 MALT1 604860
19p13.3 Hatipoglu immunodeficiency syndrome AR 3 620331 DPP9 608258
19p13.2 Immunodeficiency 35 AR 3 611521 TYK2 176941
19p13.11 Immunodeficiency 76 AR 3 619164 FCHO1 613437
19p13.11 Immunodeficiency 30 AR 3 614891 IL12RB1 601604
19q13.2 ?Immunodeficiency 62 AR 3 618459 ARHGEF1 601855
19q13.32 ?Immunodeficiency 53 AR 3 617585 RELB 604758
19q13.33 Immunodeficiency 96 AR 3 619774 LIG1 126391
19q13.33 ?Immunodeficiency 125 AR 3 620926 FLT3LG 600007
19q13.33 Immunodeficiency 120 AR 3 620836 POLD1 174761
20p11.23 ?Immunodeficiency 101 (varicella zoster virus-specific) AD 3 619872 POLR3F 617455
20p11.21 Immunodeficiency 55 AR 3 617827 GINS1 610608
20q11.23 ?Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias AR 3 619846 CTNNBL1 611537
20q13.12 T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations AR 3 614868 STK4 604965
20q13.13 Immunodeficiency 91 and hyperinflammation AR 3 619644 ZNFX1 618931
21q22.11 Immunodeficiency 45 AR 3 616669 IFNAR2 602376
21q22.11 Immunodeficiency 106, susceptibility to viral infections AR 3 619935 IFNAR1 107450
21q22.11 Immunodeficiency 28, mycobacteriosis AR 3 614889 IFNGR2 147569
21q22.3 ?Immunodeficiency 119 AR 3 620825 ICOSLG 605717
21q22.3 Immunodeficiency 114, folate-responsive AR 3 620603 SLC19A1 600424
22q11.1 Immunodeficiency 51 AR 3 613953 IL17RA 605461
22q12.3 ?Immunodeficiency 85 and autoimmunity AD 3 619510 TOM1 604700
22q12.3 Immunodeficiency 63 with lymphoproliferation and autoimmunity AR 3 618495 IL2RB 146710
22q13.1 ?Immunodeficiency 73C with defective neutrophil chemotaxis and hypogammaglobulinemia AR 3 618987 RAC2 602049
22q13.1 Immunodeficiency 73B with defective neutrophil chemotaxis and lymphopenia AD 3 618986 RAC2 602049
22q13.1 Immunodeficiency 73A with defective neutrophil chemotaxix and leukocytosis AD 3 608203 RAC2 602049
22q13.1 ?Immunodeficiency 89 and autoimmunity AR 3 619632 CARD10 607209
22q13.1-q13.2 ?Immunodeficiency 66 AR 3 618847 MKL1 606078
Xp22.2 Immunodeficiency 74, COVID19-related, X-linked XLR 3 301051 TLR7 300365
Xp22.2 Immunodeficiency 98 with autoinflammation, X-linked SMo, XL 3 301078 TLR8 300366
Xp22.12 ?Immunodeficiency 61 XLR 3 300310 SH3KBP1 300374
Xp21.1-p11.4 Immunodeficiency 34, mycobacteriosis, X-linked XLR 3 300645 CYBB 300481
Xp11.23 Wiskott-Aldrich syndrome XLR 3 301000 WAS 300392
Xq12 Immunodeficiency 50 XLR 3 300988 MSN 309845
Xq13.1 Severe combined immunodeficiency, X-linked XLR 3 300400 IL2RG 308380
Xq13.1 Combined immunodeficiency, X-linked, moderate XLR 3 312863 IL2RG 308380
Xq22.1 Agammaglobulinemia, X-linked 1 XLR 3 300755 BTK 300300
Xq24 Immunodeficiency 118, mycobacteriosis XLR 3 301115 MCTS1 300587
Xq25 Lymphoproliferative syndrome, X-linked, 1 XLR 3 308240 SH2D1A 300490
Xq26.1 Immunodeficiency 102 XLR 3 301082 SASH3 300441
Xq26.3 Immunodeficiency, X-linked, with hyper-IgM XLR 3 308230 TNFSF5 300386
Xq28 Immunodeficiency 47 XLR 3 300972 ATP6AP1 300197
Xq28 Immunodeficiency 33 XLR 3 300636 IKBKG 300248

TEXT

A number sign (#) is used with this entry because of evidence that immunodeficiency-33 (IMD33) is caused by hemizygous mutation in the gene encoding NF-kappa-B essential modulator (NEMO, or IKBKG; 300248) on chromosome Xq28.

Hemizygous mutation in the IKBKG gene can also cause the X-linked recessive disorder ectodermal dysplasia and immunodeficiency-1 (EDAID1; 300291).

Heterozygous mutation in the IKBKG gene results in X-linked dominant incontinentia pigmenti (IP; 308300) in females.


Description

Immunodeficiency-33 (IMD33) is an X-linked recessive disorder that affects only males. It is characterized by early-onset severe infections, usually due to pneumococcus, H. influenzae, and atypical mycobacteria, although other organisms have also been detected. Immunologic investigations may show variable abnormalities or may be normal. Disturbances include dysgammaglobulinemia with hypogammaglobulinemia, decreased IgG2, aberrant levels of IgM and IgA, and decreased class-switched memory B cells. There is often poor, but variable, response to vaccination; in particular, most patients do not develop antibodies to certain polysaccharide vaccines, notably pneumococcus. Other immunologic abnormalities may include impaired NK cytotoxic function, impaired cytokine production upon stimulation with IL1B (147720) or TNFA (191160), low IL6 (147620), low IL12 (see 161561), and decreased IFNG (147570). Patients do not have overt abnormalities of T-cell proliferation, although signaling pathways, such as CD40LG (300386)/CD40 (109535), may be disturbed. There is heterogeneity in the immunologic phenotype, resulting in highly variable clinical courses, most likely due to the different effects of hypomorphic mutations. Treatment with antibiotics and IVIg is usually beneficial; hematopoietic stem cell transplantation may not be necessary, but can be effective. Features of hypohidrotic ectodermal dysplasia are generally not present, although some patients may have conical teeth or hypodontia (summary by Orange et al., 2004, Filipe-Santos et al., 2006, Salt et al., 2008, Heller et al., 2020).


Clinical Features

Orange et al. (2004) reported a boy (patient 5) who developed sepsis with Haemophilus influenzae at 5 years of age after immunization, and later had a cutaneous mycobacterial infection. Medical history revealed possible earlier bacterial pneumonia. He responded to treatment for the mycobacterium without relapse. He did not have hypogammaglobulinemia, but did have decreased levels of some IgG subsets, and decreased NK cell cytotoxic activity compared to controls. The boy had no clinical evidence of ectodermal dysplasia. Orange et al. (2004) reported follow-up of this patient, who was described as a 15-year-old boy with a specific pattern of infectious susceptibility and immunodeficiency. He had pneumonia 4 times between the ages of 3 and 7 years and Haemophilus influenzae type b sepsis at age 5 years. He had a normal total IgG level, but IgG3 levels that were never greater than 10 mg/dL and no specific antibody against tetanus toxoid (despite receiving immunization) or H. influenzae polyribosyl phosphate; he was treated with immunoglobulin replacement. Laboratory studies showed variably impaired immunologic function, with reduced CD40-induced B-cell proliferation, variable Toll-like receptor-induced TNF production, and partially reduced NFKB nuclear translocation. He did not have ectodermal dysplasia and had normal dentition, hair pattern, and perspiration.

Niehues et al. (2004) reported a boy, born of healthy unrelated Polish parents living in Germany, with IMD33 without signs of ectodermal dysplasia. From the age of 15 months, he suffered from multiple episodes of disseminated Mycobacterium avium disease (affecting mostly lymph nodes and bones). At the age of 7 years, he was diagnosed with bronchiectasis caused by Haemophilus influenzae and Streptococcus pneumoniae. At the age of 11 years, the patient presented with extraintestinal disease caused by Salmonella enteritidis. At the age of 12, he developed severe autoimmune hemolytic anemia and died from herpes simplex virus 1 meningoencephalitis. Immunologic workup showed low IgA and IgG levels, with markedly high serum IgM levels and low levels of gamma-IFN. No serum antibodies against diphtheria toxoid and tetanus toxoid were detected, and titers of antibodies against H. influenzae were low despite complete routine vaccination. The patient also presented low serum titers of antibodies against S. pneumoniae and had no allohemagglutinin antibodies. Known molecular causes of hyper-IgM syndrome (308230) were excluded. The numbers of T, B, and NK lymphocytes and the proportions of the CD4+ and CD8+ T lymphocyte subsets were within normal ranges at the ages of 2 and 4 years, although he lacked memory B cells. Proliferative responses of T lymphocytes to mitogens were normal.

Ku et al. (2005) reported 2 unrelated boys with IMD33. They presented in the first years of life with recurrent severe systemic bacterial infections, including pneumococcus, H. influenzae, and Pseudomonas, as well as Candida. Immunoglobulin levels were normal, although IgM was low in 1 patient. Neither patient developed antibodies to pneumococcus, despite recurrent infections; patient 1 was unable to mount an antibody response to pneumococcal polysaccharide vaccination. However, both did respond to H. influenzae vaccine, and patient 2 mounted a response to tetanus toxoid. Neither patient had features of ectodermal dysplasia, although they had hypodontia and conical incisors. The mother of 1 patient had conical teeth, whereas the mother of the other patient had no clinical abnormalities. Heller et al. (2020) reported follow-up of one of the patients reported by Ku et al. (2005), noting that he was treated successfully with IVIg and lived an independent life at age 25.

Ku et al. (2007) described a 4.5-year-old boy, born to unrelated Belgian parents, with IMD33. He was noted to have hypodontia with conical incisors, but had only dry skin with normal sweating. He received all routine vaccinations with no adverse effect. At age 15 months, he was hospitalized for persistent fever with buccal cellulitis, caused by Streptococcus pneumoniae serotype 33. He recovered completely after intravenous cefuroxime for 7 days, but continued to have recurrent invasive infections with Streptococcus pneumoniae serotype 33. Beginning at age 23 months, he had serial vaccinations for pneumococcus, but again presented with recurrent invasive infections of Streptococcus pneumoniae serotype 23. Immunologic workup showed normal numbers of white cells and lymphocytes, normal Ig levels, and normal numbers of T, B, and NK cells. He had impaired antibody response to multiple vaccinations. Monthly prophylactic treatment with intravenous immunoglobulins was started when the patient was 3 years, 8 months old. Studies of patient fibroblasts showed impaired responses to stimulation by both IL1B and TNFA. This and other responses suggested a defect downstream of the TOLL/IL1R signaling pathway (see 603030).

Filipe-Santos et al. (2006) reported a multiplex American kindred (kindred A) in which 4 boys developed disseminated mycobacterial disease in an X-linked recessive pattern of inheritance. None of the patients had BCG vaccination, but all presented with disseminated M. avium infection between ages 5 and 14 years. Several developed other recurrent severe bacteremic infections with H. influenzae and Enterobacter. An unrelated boy of Italian/Serbian descent (kindred B) had BCG vaccination at age 2 months and presented with disseminated disease at age 2 years. At age 8 years, he was clinically well with no treatment. Another unrelated boy of German descent had recurrent infections in childhood, including bronchitis, pneumonitis, and H. influenzae, and presented at age 11 years with mycobacterial disease. In all patients, laboratory studies showed normal numbers of immune cells, normal T-cell proliferative responses, and normal immunoglobulins with proper antibody responses to vaccination, including pneumococcus, although this response was low and somewhat delayed. Detailed immunologic studies of all patients showed impaired CD40 signaling in monocytes and antigen-presenting cells, delayed nuclear accumulation of NFKB, and impaired secretion of IL12 by CD40L-expressing T cells. This resulted in impaired gamma-IFN production by T cells, ultimately resulting in increased susceptibility to mycobacterial infection. However, CD40-dependent proliferation and immunoglobulin class-switching of B cells was normal, and patients' blood and fibroblasts responded to other NFKB activators, such as TNFA, IL1B, and LPS. Some of the patients had sparse or conical teeth, which was long unrecognized, but no other features of ectodermal dysplasia.

Salt et al. (2008) reported a boy with recurrent infections, including Pneumocystis, CMV, and rotavirus. He had normal immunoglobulins and normal antibody response to diphtheria, tetanus, and H. influenzae B, but poor response to pneumococcal vaccination. Detailed immunologic studies showed impaired NK cell function and evidence of impaired T-cell receptor signaling through the NFKB pathway. Toll-like receptor function appeared to be normal. He had no evidence of ectodermal dysplasia.

Frans et al. (2017) reported a 2-year-old boy with IMD33. He presented at 1 year of age with otitis media and mastoiditis due to Pseudomonas infection, and later developed an EBV infection. Laboratory studies showed hypogammaglobulinemia, polysaccharide antibody deficiency, and low levels of switched memory B cells. Patient peripheral blood cells showed mildly impaired IL6 production in response to IL1B. He had no signs of ectodermal dysplasia. Treatment with immunoglobulin therapy resulted in clinical improvement.

Boisson et al. (2019) reported 2 brothers from a European family (family A) and a boy from a Japanese family (family B) with severe IMD33. The patients presented in infancy with severe systemic infections, including Klebsiella, respiratory syncytial virus, Enterobacter, E. coli, fungal infections, and HHV6. Although immunologic parameters were basically normal, 1 patient had no IgA and developed hypogammaglobulinemia with poor response to tetanus and H. influenzae vaccination. Two patients had other variable abnormalities, including low IgG levels, high white cells, transient neutropenia, lymphopenia, and low NK cell levels. TNFA production in response to LPS and IFNG was impaired in the 1 patient studied. None of the patients had features of ectodermal dysplasia; all died by 9 months of age. The mother in family A had mild features of IP.

Heller et al. (2020) reported a boy (patient 2) with IMD33 without ectodermal dysplasia. He had recurrent infections, including respiratory infections and oral HSV1. Immunoglobulin levels and tetanus antibodies were normal, but he had impaired response to polysaccharide vaccinations. He was successfully treated with IVIg.

Clinical Variability

Hsu et al. (2018) reported 4 adult males, including 2 sibs, who presented with disseminated mycobacterial infections between 26 and 38 years of age. All had a remote history of recurrent childhood infections, including H. influenzae. One patient had documented low IgM, increased IgA, and poor responses to pneumococcal, influenza, and measles vaccination. None had clear evidence of ectodermal dysplasia. Three of the patients died from the mycobacterial infection; the fourth patient was unable to clear the infection.


Clinical Management

Most patients with IMD33 respond well to IVIg and prophylactic antibiotics (Frans et al., 2017, Heller et al., 2020).

Some patients with IMD33 have had successful bone marrow transplantation, although the outcomes are variable and a few may have persistent colitis. The absence of ectodermal dysplasia may be associated with a better outcome (Abbott et al., 2014).


Inheritance

The transmission pattern of IMD33 in the families reported by Filipe-Santos et al. (2006) was consistent with X-linked recessive inheritance.


Molecular Genetics

In a 15-year-old boy with IMD33, Orange et al. (2004) identified a de novo hemizygous splice site mutation in the IKBKG gene (300248.0018), resulting in the skipping of exon 9 and the deletion of 19 residues, some of which affected the leucine zipper (LZ) domain. Analysis of patient peripheral blood and buccal epithelial cells showed presence of both mutant and wildtype transcripts. Western blot analysis using an antibody against the LZ domain showed barely detectable IKBKG protein levels in patient cells, whereas an antibody against the zinc finger domain showed normal protein levels. The presence of some normal transcripts may explain immunodeficiency without signs of ectodermal dysplasia in this patient. In vitro functional expression studies showed impaired, but not absent, nuclear translocation of NFKB in stimulated patient B cells compared to controls, as well as variable response to TNFA. Orange et al. (2004) postulated that exon 9 may be dispensable for ectodermal development.

In the boy with IMD33 reported by Niehues et al. (2004), Puel et al. (2006) found a hemizygous 1-bp insertion in exon 2 of the NEMO gene (300248.0019), resulting in premature termination. Puel et al. (2006) showed that a Kozakian methionine codon located immediately downstream from the insertion allowed the reinitiation of translation. The findings suggested that residual production of an NH2-truncated NEMO protein was sufficient for normal fetal development and for the subsequent normal development of skin appendages, but was insufficient for the development of protective immune responses.

In 2 unrelated boys with IMD33, Ku et al. (2005) identified hemizygous mutations in the IKBKG gene (c.811_828del, 300248.0025 and L80P, 300248.0026). The mutations occurred in the coiled-coil domains of the protein. Western blot analysis of patient cells showed presence of the IKBKG protein, but fibroblasts had poor IL6 production in response to TNFA and IL1B compared to controls. The findings were consistent with a hypomorphic allele. The patients had hypodontia and conical teeth, but no other features of ectodermal dysplasia. One carrier mother also had conical teeth.

In affected males from 3 unrelated kindreds with IMD33, Filipe-Santos et al. (2006) identified 2 hemizygous missense mutations in the NEMO gene (E315A, 300248.0021 and R319Q, 300248.0022), both of which occurred in the LZ domain and were predicted to disrupt a salt bridge. Western blot and flow cytometric analyses showed normal expression of the mutant NEMO proteins. Patient mononuclear cells responded normally to most stimuli, but IFNG (147570) and IL12 (see 161561) production in response to PHA mitogen was impaired due to defective CD40 (109535) signaling in monocytes and dendritic cells. Filipe-Santos et al. (2006) concluded that mutations in NEMO that disrupt the leucine zipper domain provide a genetic etiology to X-linked recessive immunodeficiency with a particular susceptibility to mycobacterial disease.

In a Belgian boy with IMD33, Ku et al. (2007) identified a hemizygous mutation in the IKBKG gene (R173G; 300248.0023) that resulted in abnormal splicing. Western blot analysis showed decreased levels of the protein compared to controls, consistent with partial IKBKG deficiency. The mother was heterozygous for this mutation.

In a 2-year-old boy with IMD33, Frans et al. (2017) identified a hemizygous missense mutation in the IKBKG gene (E57K; 300248.0029). The mutation affected the N-terminal domain of the protein. His mother, who also carried the mutation, had a history of recurrent sinorespiratory infections, but no signs of IP. The variant was present at a low frequency (0.001) in the ExAC database. Patient peripheral blood cells showed mildly decreased IL6 production after stimulation with IL1B compared to controls. However, NEMO expression in patient fibroblasts was normal, and IKBA was degraded normally upon stimulation with IL1B or TNFA, suggesting a specific effect of the mutation. In vitro functional expression studies in IKBKG-null cells transfected with the mutation showed mildly impaired IL6 production after stimulation with TNFA or IL1B compared to controls. Frans et al. (2017) noted that mutations affecting the N terminus of NEMO tend to lead to decreased production of immunoglobulins; the authors postulated a hypomorphic effect of this variant.

In 4 adult males from 3 unrelated families with IMD33 manifest as disseminated mycobacterial infections, Hsu et al. (2018) identified hemizygous splice site mutations in the 5-prime untranslated region of the IKBKG gene. Three patients from 2 families (families A and B) carried a c.1-16G-C transversion (300248.0030) at the last base of the first untranslated exon. The patient from family C carried a hemizygous c.1-16+G-T in the adjacent intron. Analysis of cells from the patient with the c.1-16G-C mutation showed a splicing abnormality, resulting in a 110-bp deletion at the 3-prime end of exon 1. This molecular defect resulted in decreased transcript and protein levels compared to controls (about 30%). Cells derived from the patients in families A and B failed to upregulate cytokines in response to certain TLR agonists, suggesting that this IKBKG mutation is hypomorphic.

In 3 boys from 2 families of European and Japanese descent who died from IMD33, Boisson et al. (2019) identified a deep intronic mutation (IVS4+866C-T; 300248.0024) in the IKBKG gene that created a new splicing donor site and resulted in a 44-nucleotide pseudoexon that produced a frameshift. The boy in the European family inherited the mutation from his mother, who had mild incontinentia pigmenti. The mutation in the Japanese boy occurred de novo. The variant was not found in the 1000 Genomes Project or gnomAD databases. In vitro studies showed impaired, but not abolished NFKB activation. Aberrant splicing rates differed between cell types, with wildtype NEMO mRNA and protein levels ranging from barely detectable in leukocytes to residual amounts in induced pluripotent stem cell-derived (iPSC-derived) macrophages, and higher levels in fibroblasts and iPSC-derived neuronal precursor cells.

In a boy (patient 1) with IMD33, Abbott et al. (2014) identified a hemizygous missense mutation in the first coiled-coil domain of the NEMO gene (D113N; 300248.0032). The patient had previously been reported in detail by Salt et al. (2008); his unaffected mother also carried the mutation.

Heller et al. (2020) identified a hemizygous D113N mutation in a boy with IMD33. His mother and grandmother, who were presumably unaffected, carried the heterozygous mutation. However, the proband's 40-year-old male cousin, who did not have recurrent infections and had normal response to polysaccharide antibodies, was hemizygous for D113N. Heller et al. (2020) noted that the allele frequency for this variant is rather high (0.009572), and that some suggest it may be a polymorphism (see Fusco et al., 2004).


Genotype/Phenotype Correlations

In general, patients with NKBKG mutations affecting the C-terminal zinc finger domain have a more severe clinical course with ectodermal dysplasia, whereas patients with mutations affecting the leucine zipper domain or the more N-terminal coiled-coil domains have a less severe clinical course and usually do not show features of ectodermal dysplasia, although isolated hypodontia and/or conical teeth may be present (Orange et al., 2004, Heller et al., 2020).


REFERENCES

  1. Abbott, J. K., Quinones, R. R., de la Morena, M. T., Gelfand, E. W. Successful hematopoietic cell transplantation in patients with unique NF-kappa-B essential modulator (NEMO) mutations. (Letter) Bone Marrow Transplant. 49: 1446-1447, 2014. [PubMed: 25068423, related citations] [Full Text]

  2. Boisson, B., Honda, Y., Ajiro, M., Bustamante, J., Bendavid, M., Gennery, A. R., Kawasaki, Y., Ichishima, J., Osawa, M., Nihira, H., Shiba, T., Tanaka, T., and 16 others. Rescue of recurrent deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency. J. Clin. Invest. 129: 583-597, 2019. [PubMed: 30422821, images, related citations] [Full Text]

  3. Filipe-Santos, O., Bustamante, J., Haverkamp, M. H., Vinolo, E., Ku, C.-L., Puel, A., Frucht, D. M., Christel, K., von Bernuth, H., Jouanguy, E., Feinberg, J., Durandy, A., and 25 others. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J. Exp. Med. 203: 1745-1759, 2006. [PubMed: 16818673, images, related citations] [Full Text]

  4. Frans, G., van der Werff Ten Bosch, J., Moens, L., Gijsbers, R., Changi-Ashtiani, M., Rokni-Zadeh, H., Shahrooei, M., Wuyts, G., Meyts, I., Bossuyt, X. Functional evaluation of an IKBK variant suspected to cause immunodeficiency without ectodermal dysplasia. J. Clin. Immun. 37: 801-810, 2017. [PubMed: 28993958, related citations] [Full Text]

  5. Fusco, F., Bardaro, T., Fimiani, G., Mercadante, V., Miano, M. G., Falco, G., Israel, A., Courtois, G., D'Urso, M., Ursini, M. V. Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappa-B activation. Hum. Molec. Genet. 13: 1763-1773, 2004. [PubMed: 15229184, related citations] [Full Text]

  6. Heller, S., Kolsch, U., Magg, T., Kruger, R., Scheuern, A., Schneider, H., Eichinger, A., Wahn, V., Unterwalder, N., Lorenz, M., Schwarz, K., Meisel, C., Schulz, A., Hauck, F., von Bernuth, H. T cell impairment is predictive for a severe clinical course in NEMO deficiency. J. Clin. Immun. 40: 421-434, 2020. [PubMed: 31965418, related citations] [Full Text]

  7. Hsu, A. P., Zerbe, C. S., Foruraghi, L., Iovine, N. L., Leiding, J. W., Mushatt, D. M., Wild, L., Kuhns, D. B., Holland, S. M. IKBKG (NEMO) 5-prime untranslated splice mutations lead to severe, chronic disseminated mycobacterial infections. Clin. Infect. Dis. 67: 456-459, 2018. [PubMed: 29534156, related citations] [Full Text]

  8. Ku, C.-L., Dupuis-Girod, S., Dittrich, A.-M., Bustamante, J., Santos, O. F., Schulze, I., Bertrand, Y., Couly, G., Bodemer, C., Bossuyt, X., Picard, C., Casanova, J.-L. NEMO mutations in 2 unrelated boys with severe infections and conical teeth. Pediatrics 115: e615, 2005. Note: Electronic Article. [PubMed: 15833888, related citations] [Full Text]

  9. Ku, C.-L., Picard, C., Erdos, M., Jeurissen, A., Bustamante, J., Puel, A., von Bernuth, H., Filipe-Santos, O., Chang, H.-H., Lawrence, T., Raes, M., Marodi, L., Bossuyt, X., Casanova, J.-L. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44: 16-23, 2007. [PubMed: 16950813, images, related citations] [Full Text]

  10. Niehues, T., Reichenbach, J., Neubert, J., Gudowius, S., Puel, A., Horneff, G., Lainka, E., Dirksen, U., Schroten, H., Doffinger, R., Casanova, J. L., Wahn, V. Nuclear factor kappa B essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J. Allergy Clin. Immun. 114: 1456-1462, 2004. [PubMed: 15577852, related citations] [Full Text]

  11. Orange, J. S., Jain, A., Ballas, Z. K., Schneider, L. C., Geha, R. S., Bonilla, F. A. The presentation and natural history of immunodeficiency caused by nuclear factor kappa-B essential modulator mutation. J. Allergy Clin. Immun. 113: 725-733, 2004. [PubMed: 15100680, related citations] [Full Text]

  12. Orange, J. S., Levy, O., Brodeur, S. R., Krzewski, K., Roy, R. M., Niemela, J. E., Fleisher, T. A., Bonilla, F. A., Geha, R. S. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J. Allergy Clin. Immun. 114: 650-656, 2004. [PubMed: 15356572, related citations] [Full Text]

  13. Puel, A., Reichenbach, J., Bustamante, J., Ku, C.-L., Feinberg, J., Doffinger, R., Bonnet, M., Filipe-Santos, O., de Beaucoudrey, L., Durandy, A., Horneff, G., Novelli, F., Wahn, V., Smahi, A., Israel, A., Niehues, T., Casanova, J.-L. The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am. J. Hum. Genet. 78: 691-701, 2006. [PubMed: 16532398, images, related citations] [Full Text]

  14. Salt, B. H., Niemela, J. E., Pandey, R., Hanson, E. P., Deering, R. P., Quinones, R., Jain, A., Orange, J. S., Gelfand, E. W. IKBKG (nuclear factor-kappa-B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J. Allergy Clin. Immun. 121: 976-982, 2008. [PubMed: 18179816, images, related citations] [Full Text]


Cassandra L. Kniffin - updated : 06/03/2020
Matthew B. Gross - updated : 2/5/2007
Creation Date:
Paul J. Converse : 2/5/2007
carol : 06/02/2022
carol : 06/10/2020
carol : 06/09/2020
ckniffin : 06/03/2020
carol : 07/13/2016
ckniffin : 6/6/2016
mgross : 5/14/2015
mgross : 12/9/2014
mgross : 9/8/2014
mgross : 9/8/2014
mgross : 9/8/2014
mgross : 3/26/2007
mgross : 3/22/2007
mgross : 3/22/2007
terry : 3/9/2007
mgross : 2/28/2007
mgross : 2/5/2007
mgross : 2/5/2007
mgross : 2/5/2007

# 300636

IMMUNODEFICIENCY 33; IMD33


Alternative titles; symbols

INVASIVE PNEUMOCOCCAL DISEASE, RECURRENT ISOLATED, 2, FORMERLY; IPD2, FORMERLY


ORPHA: 319605, 319612;   DO: 0112003;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
Xq28 Immunodeficiency 33 300636 X-linked recessive 3 IKBKG 300248

TEXT

A number sign (#) is used with this entry because of evidence that immunodeficiency-33 (IMD33) is caused by hemizygous mutation in the gene encoding NF-kappa-B essential modulator (NEMO, or IKBKG; 300248) on chromosome Xq28.

Hemizygous mutation in the IKBKG gene can also cause the X-linked recessive disorder ectodermal dysplasia and immunodeficiency-1 (EDAID1; 300291).

Heterozygous mutation in the IKBKG gene results in X-linked dominant incontinentia pigmenti (IP; 308300) in females.


Description

Immunodeficiency-33 (IMD33) is an X-linked recessive disorder that affects only males. It is characterized by early-onset severe infections, usually due to pneumococcus, H. influenzae, and atypical mycobacteria, although other organisms have also been detected. Immunologic investigations may show variable abnormalities or may be normal. Disturbances include dysgammaglobulinemia with hypogammaglobulinemia, decreased IgG2, aberrant levels of IgM and IgA, and decreased class-switched memory B cells. There is often poor, but variable, response to vaccination; in particular, most patients do not develop antibodies to certain polysaccharide vaccines, notably pneumococcus. Other immunologic abnormalities may include impaired NK cytotoxic function, impaired cytokine production upon stimulation with IL1B (147720) or TNFA (191160), low IL6 (147620), low IL12 (see 161561), and decreased IFNG (147570). Patients do not have overt abnormalities of T-cell proliferation, although signaling pathways, such as CD40LG (300386)/CD40 (109535), may be disturbed. There is heterogeneity in the immunologic phenotype, resulting in highly variable clinical courses, most likely due to the different effects of hypomorphic mutations. Treatment with antibiotics and IVIg is usually beneficial; hematopoietic stem cell transplantation may not be necessary, but can be effective. Features of hypohidrotic ectodermal dysplasia are generally not present, although some patients may have conical teeth or hypodontia (summary by Orange et al., 2004, Filipe-Santos et al., 2006, Salt et al., 2008, Heller et al., 2020).


Clinical Features

Orange et al. (2004) reported a boy (patient 5) who developed sepsis with Haemophilus influenzae at 5 years of age after immunization, and later had a cutaneous mycobacterial infection. Medical history revealed possible earlier bacterial pneumonia. He responded to treatment for the mycobacterium without relapse. He did not have hypogammaglobulinemia, but did have decreased levels of some IgG subsets, and decreased NK cell cytotoxic activity compared to controls. The boy had no clinical evidence of ectodermal dysplasia. Orange et al. (2004) reported follow-up of this patient, who was described as a 15-year-old boy with a specific pattern of infectious susceptibility and immunodeficiency. He had pneumonia 4 times between the ages of 3 and 7 years and Haemophilus influenzae type b sepsis at age 5 years. He had a normal total IgG level, but IgG3 levels that were never greater than 10 mg/dL and no specific antibody against tetanus toxoid (despite receiving immunization) or H. influenzae polyribosyl phosphate; he was treated with immunoglobulin replacement. Laboratory studies showed variably impaired immunologic function, with reduced CD40-induced B-cell proliferation, variable Toll-like receptor-induced TNF production, and partially reduced NFKB nuclear translocation. He did not have ectodermal dysplasia and had normal dentition, hair pattern, and perspiration.

Niehues et al. (2004) reported a boy, born of healthy unrelated Polish parents living in Germany, with IMD33 without signs of ectodermal dysplasia. From the age of 15 months, he suffered from multiple episodes of disseminated Mycobacterium avium disease (affecting mostly lymph nodes and bones). At the age of 7 years, he was diagnosed with bronchiectasis caused by Haemophilus influenzae and Streptococcus pneumoniae. At the age of 11 years, the patient presented with extraintestinal disease caused by Salmonella enteritidis. At the age of 12, he developed severe autoimmune hemolytic anemia and died from herpes simplex virus 1 meningoencephalitis. Immunologic workup showed low IgA and IgG levels, with markedly high serum IgM levels and low levels of gamma-IFN. No serum antibodies against diphtheria toxoid and tetanus toxoid were detected, and titers of antibodies against H. influenzae were low despite complete routine vaccination. The patient also presented low serum titers of antibodies against S. pneumoniae and had no allohemagglutinin antibodies. Known molecular causes of hyper-IgM syndrome (308230) were excluded. The numbers of T, B, and NK lymphocytes and the proportions of the CD4+ and CD8+ T lymphocyte subsets were within normal ranges at the ages of 2 and 4 years, although he lacked memory B cells. Proliferative responses of T lymphocytes to mitogens were normal.

Ku et al. (2005) reported 2 unrelated boys with IMD33. They presented in the first years of life with recurrent severe systemic bacterial infections, including pneumococcus, H. influenzae, and Pseudomonas, as well as Candida. Immunoglobulin levels were normal, although IgM was low in 1 patient. Neither patient developed antibodies to pneumococcus, despite recurrent infections; patient 1 was unable to mount an antibody response to pneumococcal polysaccharide vaccination. However, both did respond to H. influenzae vaccine, and patient 2 mounted a response to tetanus toxoid. Neither patient had features of ectodermal dysplasia, although they had hypodontia and conical incisors. The mother of 1 patient had conical teeth, whereas the mother of the other patient had no clinical abnormalities. Heller et al. (2020) reported follow-up of one of the patients reported by Ku et al. (2005), noting that he was treated successfully with IVIg and lived an independent life at age 25.

Ku et al. (2007) described a 4.5-year-old boy, born to unrelated Belgian parents, with IMD33. He was noted to have hypodontia with conical incisors, but had only dry skin with normal sweating. He received all routine vaccinations with no adverse effect. At age 15 months, he was hospitalized for persistent fever with buccal cellulitis, caused by Streptococcus pneumoniae serotype 33. He recovered completely after intravenous cefuroxime for 7 days, but continued to have recurrent invasive infections with Streptococcus pneumoniae serotype 33. Beginning at age 23 months, he had serial vaccinations for pneumococcus, but again presented with recurrent invasive infections of Streptococcus pneumoniae serotype 23. Immunologic workup showed normal numbers of white cells and lymphocytes, normal Ig levels, and normal numbers of T, B, and NK cells. He had impaired antibody response to multiple vaccinations. Monthly prophylactic treatment with intravenous immunoglobulins was started when the patient was 3 years, 8 months old. Studies of patient fibroblasts showed impaired responses to stimulation by both IL1B and TNFA. This and other responses suggested a defect downstream of the TOLL/IL1R signaling pathway (see 603030).

Filipe-Santos et al. (2006) reported a multiplex American kindred (kindred A) in which 4 boys developed disseminated mycobacterial disease in an X-linked recessive pattern of inheritance. None of the patients had BCG vaccination, but all presented with disseminated M. avium infection between ages 5 and 14 years. Several developed other recurrent severe bacteremic infections with H. influenzae and Enterobacter. An unrelated boy of Italian/Serbian descent (kindred B) had BCG vaccination at age 2 months and presented with disseminated disease at age 2 years. At age 8 years, he was clinically well with no treatment. Another unrelated boy of German descent had recurrent infections in childhood, including bronchitis, pneumonitis, and H. influenzae, and presented at age 11 years with mycobacterial disease. In all patients, laboratory studies showed normal numbers of immune cells, normal T-cell proliferative responses, and normal immunoglobulins with proper antibody responses to vaccination, including pneumococcus, although this response was low and somewhat delayed. Detailed immunologic studies of all patients showed impaired CD40 signaling in monocytes and antigen-presenting cells, delayed nuclear accumulation of NFKB, and impaired secretion of IL12 by CD40L-expressing T cells. This resulted in impaired gamma-IFN production by T cells, ultimately resulting in increased susceptibility to mycobacterial infection. However, CD40-dependent proliferation and immunoglobulin class-switching of B cells was normal, and patients' blood and fibroblasts responded to other NFKB activators, such as TNFA, IL1B, and LPS. Some of the patients had sparse or conical teeth, which was long unrecognized, but no other features of ectodermal dysplasia.

Salt et al. (2008) reported a boy with recurrent infections, including Pneumocystis, CMV, and rotavirus. He had normal immunoglobulins and normal antibody response to diphtheria, tetanus, and H. influenzae B, but poor response to pneumococcal vaccination. Detailed immunologic studies showed impaired NK cell function and evidence of impaired T-cell receptor signaling through the NFKB pathway. Toll-like receptor function appeared to be normal. He had no evidence of ectodermal dysplasia.

Frans et al. (2017) reported a 2-year-old boy with IMD33. He presented at 1 year of age with otitis media and mastoiditis due to Pseudomonas infection, and later developed an EBV infection. Laboratory studies showed hypogammaglobulinemia, polysaccharide antibody deficiency, and low levels of switched memory B cells. Patient peripheral blood cells showed mildly impaired IL6 production in response to IL1B. He had no signs of ectodermal dysplasia. Treatment with immunoglobulin therapy resulted in clinical improvement.

Boisson et al. (2019) reported 2 brothers from a European family (family A) and a boy from a Japanese family (family B) with severe IMD33. The patients presented in infancy with severe systemic infections, including Klebsiella, respiratory syncytial virus, Enterobacter, E. coli, fungal infections, and HHV6. Although immunologic parameters were basically normal, 1 patient had no IgA and developed hypogammaglobulinemia with poor response to tetanus and H. influenzae vaccination. Two patients had other variable abnormalities, including low IgG levels, high white cells, transient neutropenia, lymphopenia, and low NK cell levels. TNFA production in response to LPS and IFNG was impaired in the 1 patient studied. None of the patients had features of ectodermal dysplasia; all died by 9 months of age. The mother in family A had mild features of IP.

Heller et al. (2020) reported a boy (patient 2) with IMD33 without ectodermal dysplasia. He had recurrent infections, including respiratory infections and oral HSV1. Immunoglobulin levels and tetanus antibodies were normal, but he had impaired response to polysaccharide vaccinations. He was successfully treated with IVIg.

Clinical Variability

Hsu et al. (2018) reported 4 adult males, including 2 sibs, who presented with disseminated mycobacterial infections between 26 and 38 years of age. All had a remote history of recurrent childhood infections, including H. influenzae. One patient had documented low IgM, increased IgA, and poor responses to pneumococcal, influenza, and measles vaccination. None had clear evidence of ectodermal dysplasia. Three of the patients died from the mycobacterial infection; the fourth patient was unable to clear the infection.


Clinical Management

Most patients with IMD33 respond well to IVIg and prophylactic antibiotics (Frans et al., 2017, Heller et al., 2020).

Some patients with IMD33 have had successful bone marrow transplantation, although the outcomes are variable and a few may have persistent colitis. The absence of ectodermal dysplasia may be associated with a better outcome (Abbott et al., 2014).


Inheritance

The transmission pattern of IMD33 in the families reported by Filipe-Santos et al. (2006) was consistent with X-linked recessive inheritance.


Molecular Genetics

In a 15-year-old boy with IMD33, Orange et al. (2004) identified a de novo hemizygous splice site mutation in the IKBKG gene (300248.0018), resulting in the skipping of exon 9 and the deletion of 19 residues, some of which affected the leucine zipper (LZ) domain. Analysis of patient peripheral blood and buccal epithelial cells showed presence of both mutant and wildtype transcripts. Western blot analysis using an antibody against the LZ domain showed barely detectable IKBKG protein levels in patient cells, whereas an antibody against the zinc finger domain showed normal protein levels. The presence of some normal transcripts may explain immunodeficiency without signs of ectodermal dysplasia in this patient. In vitro functional expression studies showed impaired, but not absent, nuclear translocation of NFKB in stimulated patient B cells compared to controls, as well as variable response to TNFA. Orange et al. (2004) postulated that exon 9 may be dispensable for ectodermal development.

In the boy with IMD33 reported by Niehues et al. (2004), Puel et al. (2006) found a hemizygous 1-bp insertion in exon 2 of the NEMO gene (300248.0019), resulting in premature termination. Puel et al. (2006) showed that a Kozakian methionine codon located immediately downstream from the insertion allowed the reinitiation of translation. The findings suggested that residual production of an NH2-truncated NEMO protein was sufficient for normal fetal development and for the subsequent normal development of skin appendages, but was insufficient for the development of protective immune responses.

In 2 unrelated boys with IMD33, Ku et al. (2005) identified hemizygous mutations in the IKBKG gene (c.811_828del, 300248.0025 and L80P, 300248.0026). The mutations occurred in the coiled-coil domains of the protein. Western blot analysis of patient cells showed presence of the IKBKG protein, but fibroblasts had poor IL6 production in response to TNFA and IL1B compared to controls. The findings were consistent with a hypomorphic allele. The patients had hypodontia and conical teeth, but no other features of ectodermal dysplasia. One carrier mother also had conical teeth.

In affected males from 3 unrelated kindreds with IMD33, Filipe-Santos et al. (2006) identified 2 hemizygous missense mutations in the NEMO gene (E315A, 300248.0021 and R319Q, 300248.0022), both of which occurred in the LZ domain and were predicted to disrupt a salt bridge. Western blot and flow cytometric analyses showed normal expression of the mutant NEMO proteins. Patient mononuclear cells responded normally to most stimuli, but IFNG (147570) and IL12 (see 161561) production in response to PHA mitogen was impaired due to defective CD40 (109535) signaling in monocytes and dendritic cells. Filipe-Santos et al. (2006) concluded that mutations in NEMO that disrupt the leucine zipper domain provide a genetic etiology to X-linked recessive immunodeficiency with a particular susceptibility to mycobacterial disease.

In a Belgian boy with IMD33, Ku et al. (2007) identified a hemizygous mutation in the IKBKG gene (R173G; 300248.0023) that resulted in abnormal splicing. Western blot analysis showed decreased levels of the protein compared to controls, consistent with partial IKBKG deficiency. The mother was heterozygous for this mutation.

In a 2-year-old boy with IMD33, Frans et al. (2017) identified a hemizygous missense mutation in the IKBKG gene (E57K; 300248.0029). The mutation affected the N-terminal domain of the protein. His mother, who also carried the mutation, had a history of recurrent sinorespiratory infections, but no signs of IP. The variant was present at a low frequency (0.001) in the ExAC database. Patient peripheral blood cells showed mildly decreased IL6 production after stimulation with IL1B compared to controls. However, NEMO expression in patient fibroblasts was normal, and IKBA was degraded normally upon stimulation with IL1B or TNFA, suggesting a specific effect of the mutation. In vitro functional expression studies in IKBKG-null cells transfected with the mutation showed mildly impaired IL6 production after stimulation with TNFA or IL1B compared to controls. Frans et al. (2017) noted that mutations affecting the N terminus of NEMO tend to lead to decreased production of immunoglobulins; the authors postulated a hypomorphic effect of this variant.

In 4 adult males from 3 unrelated families with IMD33 manifest as disseminated mycobacterial infections, Hsu et al. (2018) identified hemizygous splice site mutations in the 5-prime untranslated region of the IKBKG gene. Three patients from 2 families (families A and B) carried a c.1-16G-C transversion (300248.0030) at the last base of the first untranslated exon. The patient from family C carried a hemizygous c.1-16+G-T in the adjacent intron. Analysis of cells from the patient with the c.1-16G-C mutation showed a splicing abnormality, resulting in a 110-bp deletion at the 3-prime end of exon 1. This molecular defect resulted in decreased transcript and protein levels compared to controls (about 30%). Cells derived from the patients in families A and B failed to upregulate cytokines in response to certain TLR agonists, suggesting that this IKBKG mutation is hypomorphic.

In 3 boys from 2 families of European and Japanese descent who died from IMD33, Boisson et al. (2019) identified a deep intronic mutation (IVS4+866C-T; 300248.0024) in the IKBKG gene that created a new splicing donor site and resulted in a 44-nucleotide pseudoexon that produced a frameshift. The boy in the European family inherited the mutation from his mother, who had mild incontinentia pigmenti. The mutation in the Japanese boy occurred de novo. The variant was not found in the 1000 Genomes Project or gnomAD databases. In vitro studies showed impaired, but not abolished NFKB activation. Aberrant splicing rates differed between cell types, with wildtype NEMO mRNA and protein levels ranging from barely detectable in leukocytes to residual amounts in induced pluripotent stem cell-derived (iPSC-derived) macrophages, and higher levels in fibroblasts and iPSC-derived neuronal precursor cells.

In a boy (patient 1) with IMD33, Abbott et al. (2014) identified a hemizygous missense mutation in the first coiled-coil domain of the NEMO gene (D113N; 300248.0032). The patient had previously been reported in detail by Salt et al. (2008); his unaffected mother also carried the mutation.

Heller et al. (2020) identified a hemizygous D113N mutation in a boy with IMD33. His mother and grandmother, who were presumably unaffected, carried the heterozygous mutation. However, the proband's 40-year-old male cousin, who did not have recurrent infections and had normal response to polysaccharide antibodies, was hemizygous for D113N. Heller et al. (2020) noted that the allele frequency for this variant is rather high (0.009572), and that some suggest it may be a polymorphism (see Fusco et al., 2004).


Genotype/Phenotype Correlations

In general, patients with NKBKG mutations affecting the C-terminal zinc finger domain have a more severe clinical course with ectodermal dysplasia, whereas patients with mutations affecting the leucine zipper domain or the more N-terminal coiled-coil domains have a less severe clinical course and usually do not show features of ectodermal dysplasia, although isolated hypodontia and/or conical teeth may be present (Orange et al., 2004, Heller et al., 2020).


REFERENCES

  1. Abbott, J. K., Quinones, R. R., de la Morena, M. T., Gelfand, E. W. Successful hematopoietic cell transplantation in patients with unique NF-kappa-B essential modulator (NEMO) mutations. (Letter) Bone Marrow Transplant. 49: 1446-1447, 2014. [PubMed: 25068423] [Full Text: https://doi.org/10.1038/bmt.2014.157]

  2. Boisson, B., Honda, Y., Ajiro, M., Bustamante, J., Bendavid, M., Gennery, A. R., Kawasaki, Y., Ichishima, J., Osawa, M., Nihira, H., Shiba, T., Tanaka, T., and 16 others. Rescue of recurrent deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency. J. Clin. Invest. 129: 583-597, 2019. [PubMed: 30422821] [Full Text: https://doi.org/10.1172/JCI124011]

  3. Filipe-Santos, O., Bustamante, J., Haverkamp, M. H., Vinolo, E., Ku, C.-L., Puel, A., Frucht, D. M., Christel, K., von Bernuth, H., Jouanguy, E., Feinberg, J., Durandy, A., and 25 others. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J. Exp. Med. 203: 1745-1759, 2006. [PubMed: 16818673] [Full Text: https://doi.org/10.1084/jem.20060085]

  4. Frans, G., van der Werff Ten Bosch, J., Moens, L., Gijsbers, R., Changi-Ashtiani, M., Rokni-Zadeh, H., Shahrooei, M., Wuyts, G., Meyts, I., Bossuyt, X. Functional evaluation of an IKBK variant suspected to cause immunodeficiency without ectodermal dysplasia. J. Clin. Immun. 37: 801-810, 2017. [PubMed: 28993958] [Full Text: https://doi.org/10.1007/s10875-017-0448-9]

  5. Fusco, F., Bardaro, T., Fimiani, G., Mercadante, V., Miano, M. G., Falco, G., Israel, A., Courtois, G., D'Urso, M., Ursini, M. V. Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappa-B activation. Hum. Molec. Genet. 13: 1763-1773, 2004. [PubMed: 15229184] [Full Text: https://doi.org/10.1093/hmg/ddh192]

  6. Heller, S., Kolsch, U., Magg, T., Kruger, R., Scheuern, A., Schneider, H., Eichinger, A., Wahn, V., Unterwalder, N., Lorenz, M., Schwarz, K., Meisel, C., Schulz, A., Hauck, F., von Bernuth, H. T cell impairment is predictive for a severe clinical course in NEMO deficiency. J. Clin. Immun. 40: 421-434, 2020. [PubMed: 31965418] [Full Text: https://doi.org/10.1007/s10875-019-00728-y]

  7. Hsu, A. P., Zerbe, C. S., Foruraghi, L., Iovine, N. L., Leiding, J. W., Mushatt, D. M., Wild, L., Kuhns, D. B., Holland, S. M. IKBKG (NEMO) 5-prime untranslated splice mutations lead to severe, chronic disseminated mycobacterial infections. Clin. Infect. Dis. 67: 456-459, 2018. [PubMed: 29534156] [Full Text: https://doi.org/10.1093/cid/ciy186]

  8. Ku, C.-L., Dupuis-Girod, S., Dittrich, A.-M., Bustamante, J., Santos, O. F., Schulze, I., Bertrand, Y., Couly, G., Bodemer, C., Bossuyt, X., Picard, C., Casanova, J.-L. NEMO mutations in 2 unrelated boys with severe infections and conical teeth. Pediatrics 115: e615, 2005. Note: Electronic Article. [PubMed: 15833888] [Full Text: https://doi.org/10.1542/peds.2004-1754]

  9. Ku, C.-L., Picard, C., Erdos, M., Jeurissen, A., Bustamante, J., Puel, A., von Bernuth, H., Filipe-Santos, O., Chang, H.-H., Lawrence, T., Raes, M., Marodi, L., Bossuyt, X., Casanova, J.-L. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44: 16-23, 2007. [PubMed: 16950813] [Full Text: https://doi.org/10.1136/jmg.2006.044446]

  10. Niehues, T., Reichenbach, J., Neubert, J., Gudowius, S., Puel, A., Horneff, G., Lainka, E., Dirksen, U., Schroten, H., Doffinger, R., Casanova, J. L., Wahn, V. Nuclear factor kappa B essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J. Allergy Clin. Immun. 114: 1456-1462, 2004. [PubMed: 15577852] [Full Text: https://doi.org/10.1016/j.jaci.2004.08.047]

  11. Orange, J. S., Jain, A., Ballas, Z. K., Schneider, L. C., Geha, R. S., Bonilla, F. A. The presentation and natural history of immunodeficiency caused by nuclear factor kappa-B essential modulator mutation. J. Allergy Clin. Immun. 113: 725-733, 2004. [PubMed: 15100680] [Full Text: https://doi.org/10.1016/j.jaci.2004.01.762]

  12. Orange, J. S., Levy, O., Brodeur, S. R., Krzewski, K., Roy, R. M., Niemela, J. E., Fleisher, T. A., Bonilla, F. A., Geha, R. S. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J. Allergy Clin. Immun. 114: 650-656, 2004. [PubMed: 15356572] [Full Text: https://doi.org/10.1016/j.jaci.2004.06.052]

  13. Puel, A., Reichenbach, J., Bustamante, J., Ku, C.-L., Feinberg, J., Doffinger, R., Bonnet, M., Filipe-Santos, O., de Beaucoudrey, L., Durandy, A., Horneff, G., Novelli, F., Wahn, V., Smahi, A., Israel, A., Niehues, T., Casanova, J.-L. The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am. J. Hum. Genet. 78: 691-701, 2006. [PubMed: 16532398] [Full Text: https://doi.org/10.1086/501532]

  14. Salt, B. H., Niemela, J. E., Pandey, R., Hanson, E. P., Deering, R. P., Quinones, R., Jain, A., Orange, J. S., Gelfand, E. W. IKBKG (nuclear factor-kappa-B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J. Allergy Clin. Immun. 121: 976-982, 2008. [PubMed: 18179816] [Full Text: https://doi.org/10.1016/j.jaci.2007.11.014]


Contributors:
Cassandra L. Kniffin - updated : 06/03/2020
Matthew B. Gross - updated : 2/5/2007

Creation Date:
Paul J. Converse : 2/5/2007

Edit History:
carol : 06/02/2022
carol : 06/10/2020
carol : 06/09/2020
ckniffin : 06/03/2020
carol : 07/13/2016
ckniffin : 6/6/2016
mgross : 5/14/2015
mgross : 12/9/2014
mgross : 9/8/2014
mgross : 9/8/2014
mgross : 9/8/2014
mgross : 3/26/2007
mgross : 3/22/2007
mgross : 3/22/2007
terry : 3/9/2007
mgross : 2/28/2007
mgross : 2/5/2007
mgross : 2/5/2007
mgross : 2/5/2007